Oncocross and JW Pharmaceutical Expand their Partnership to Develop New Therapies Using AI in Anticancer and Regenerative Medicine
Shots:
- Oncocross & JW Pharmaceutical have entered into a joint research agreement on May 22, 2024, to develop therapies using the AI platform. The companies will research new indications for JW Pharmaceutical's FIC anticancer & regenerative medicine drug pipeline
- The partnership will leverage Oncocross’s AI platform, RAPTOR AI, facilitating the screening of indications for new or existing therapies with greater accuracy & less development time vs traditional methods
- Earlier in 2022, the companies joined hands to find new indications for drugs. The data generated via the collaboration led JW Pharmaceutical to expand an orphan disease indication for the new product, with a follow-up development plan underway
Ref: Businesswire | Image: Oncocross
Related News:- Aktis Oncology and Eli Lilly Collaborate to Discover and Develop Novel Anticancer Radiopharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
